wilate, a plasma-derived VWF/factor VIII concentrate (pdVWF/FVIII) containing VWF and FVIII in a physiological 1:1 activity ratio, is licensed for on-demand treatment, surgical prophylaxis, and regular prophylaxis in patients with VWD.13, 14The prospective, 12-month WIL-31 study (NCT04052698; WILPROPHY) evaluated the efficacy and safety of wilate prophylaxis in patients with VWD who had received prior on-demand treatment with any pdVWF/FVIII for 6 months in the prospective WIL-29 study (NCT04053699). The gene discussed is VWF; the disease is von Willebrand disease (hereditary or acquired).